Information for Sponsors & CROs

Site Experience

In 2022 we committed to opening the first clinical trial site for psychedelic assisted therapy in Northern Ireland and have ambitions to grow the psychedelic research in areas specific to our patient population. We specialise in advancing psychiatric care through clinical research with a proven track record of delivering high-quality data, strong recruitment performance, and a commitment to patient safety. 

Research Experience

  • 2022-2025: Developing EMDR derived early interventions for first responders.

  • 2023-2024: Open Label, Phase 2, Methylone for PTSD

  • 2024-2025: Placebo Controlled, Phase 2, Methylone for PTSD

  • 2024-2025: Open Label Extension, Phase 2, Methylone for PTSD

Clinical Performance

  • Data Quality < 5% query rate on entries

  • Extensive patient database with registered interest

  • Partnerships with local healthcare trusts and GP ’s 

  • Proven recruitment targets & timelines 

  • Start-up timeline CDA to FPFV 12-16 weeks.

Site Facilities

Regulatory Compliance

  • Temperature control, secured on-site Investigational Product storage

  • Northern Ireland Dept. of Health Controlled Drug License, Schedule 1

  • Regulated by annual RQIA inspection

  • Onsite carpark with disabled parking spaces

  • Accessibility bathroom and downstairs clinical/dosing space

Dosing Rooms

  • 3 private dosing rooms dedicated to clinical research

  • Welcoming spaces, soft furnishings, with low adjustable lighting

  • 2 window-less rooms for an immersive experience

  • Sound-proofed environment.

  • Video and audio recording equipment.

  • Bose sound system

Clinical Operations

  • MAC 2000 ECG Machine

  • BIHS / ESH approved Vital Signs monitoring equipment

  • In-house biological specimen collection and handling

  • Private accredited courier for sample transport

  • Contract availability with local laboratory for fast sample resulting

Site Statistics

A plain light blue background

Engagement

Retention rate >90% for
enrolled participants

Solid orange background with no distinguishable objects or features.

Support

60% screening to
study completion rate

Light purple background with subtle texture.

Connection

Extensive patient database
350+ contacts

A green bottle of a beverage on a white background.

Action

Start-up timeline from CTA signed
to FPFV <12 Weeks

Our Location

Mirabilis Health, based in Newtownabbey, Northern Ireland, offers access to an untapped demographic with cross-border reach into both the Republic of Ireland (RoI) and the wider United Kingdom (UK). Northern Ireland is home to a growing population of just under 2 million residents, with proximity to the 5 million+ population of Ireland, creating a unique and efficient recruitment landscape.

Crucially, Northern Ireland’s legacy of political conflict—commonly referred to as the Troubles, has left a lasting imprint on the collective mental health of its population. The region reports significantly higher rates of trauma-related disorders and mental health conditions per capita than other parts of the UK. This makes it not only a site of clinical need, but also one of scientific relevance for studies in trauma, PTSD, depression, anxiety, and emerging interventions such as psychedelic-assisted therapy.

Mirabilis Health combines clinical excellence, rapid startup capability, and high participant engagement—positioning us as a strategic partner for sponsors and CROs seeking both scientific depth and operational agility.

Mirabilis Health is an experienced clinical research site with facilities that offer comprehensive support, including expert clinical oversight and adherence to regulatory standards.

In 2022 we committed to opening the first clinical trial site for psychedelic assisted therapy in Northern Ireland and have ambitions to grow the psychedelic research in areas specific to our patient population. Mirabilis Health Institute is situated a short drive (approx. 15 minutes) from Belfast City Centre and approx. 2hours from Dublin City Centre.

 

Meet the team:

Black and white portrait of a middle-aged man with glasses, a trimmed beard, wearing a suit jacket, white shirt, and a patterned pocket square. He is sitting with hands folded and slightly smiling in front of a plain background.

Prof Paul W. Miller MD D MRCPsych FRSA

Consultant Psychiatrist, Clinical Lead

Black and white photo of a woman sitting on a chair, gazing to the side with a slight smile, wearing a black top, choker, and rings.

Ms Corinna Marr, BA. BSc. RN

Clinical Trial Manager

Black and white portrait of a smiling man sitting in a chair, wearing a light-colored jacket, a button-up shirt, and a watch on his left wrist.

Mr Jack Simpson

Clinical Trial Coordinator, Therapist

Black and white portrait of a woman with wavy blonde hair, sitting with arms crossed, looking off to the side, wearing a dark shirt, against a plain light background.

Mrs Katy Stewart MD

Clinical Research Physician

Black and white photo of a woman with shoulder-length hair, smiling, sitting on a chair against a plain wall, wearing a floral patterned top.

Ms Ruth O’Connor

Research Nurse

Psychedelic Training:

  • Certified Psychedelic-Assisted Therapy Provider by Integrative Psychiatry Institute, 1 year / 256 hours of training, Prof. Miller.

  • Additionally, 9 Mentors completed Foundation Mentor Training - hosted by Beckley Academy.

Specialist Areas:

  • Depression (MDD, TRD)

  • Anxiety Disorders (GAD)

  • Schizophrenia and Psychotic Disorders

  • PTSD and Trauma-related Disorders

Talk to us about your next trial